Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Research & Development: 2016-2022

Historic Research & Development for Collegium Pharmaceutical (COLL) over the last 6 years, with Mar 2022 value amounting to $4.0 million.

  • Collegium Pharmaceutical's Research & Development rose 35.94% to $4.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $10.5 million, marking a year-over-year increase of 4.66%. This contributed to the annual value of $4.0 million for FY2022, which is 57.86% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Research & Development of $4.0 million as of Q1 2022, which was up 147.55% from $1.6 million recorded in Q4 2021.
  • Over the past 5 years, Collegium Pharmaceutical's Research & Development peaked at $4.0 million during Q1 2022, and registered a low of $1.4 million during Q3 2021.
  • Its 3-year average for Research & Development is $2.6 million, with a median of $2.5 million in 2020.
  • Examining YoY changes over the last 5 years, Collegium Pharmaceutical's Research & Development showed a top increase of 38.87% in 2021 and a maximum decrease of 34.91% in 2021.
  • Collegium Pharmaceutical's Research & Development (Quarterly) stood at $2.2 million in 2018, then climbed by 6.63% to $2.4 million in 2019, then rose by 3.09% to $2.5 million in 2020, then tumbled by 34.91% to $1.6 million in 2021, then spiked by 35.94% to $4.0 million in 2022.
  • Its last three reported values are $4.0 million in Q1 2022, $1.6 million for Q4 2021, and $1.4 million during Q3 2021.